Summary of the demographics of subjects and the clinical profile of the patients*
| Characteristic | Group, treatment; mean (and standard deviation) | Controls (n = 12) | ||
|---|---|---|---|---|
| Patients | ||||
| AVH (n = 8) | N-AVH (n = 10) | All (n = 18) | ||
| Age, yr | 37.3 (6.6) | 37.4 (8.8) | 37.3 (7.7) | 42 (12) |
| Level of education, yr | 12.3 (2) | 12.6 (1) | 12.6 (1.6) | 15 (2.4) |
| Verbal intelligence* | 10.2 (2.6) | 9.9 (2.3) | 10 (2.3) | 12 (3.8) |
| Duration of illness, yr* | 14 (8) | 13.5 (9.4) | 13.8 (8.5) | N/A |
| Medications (chlorpomazine equivalence), mg | 507 (73) | 562 (605) | 536 (431) | N/A |
| (n = 5) | (n = 6) | (n = 11) | N/A | |
| PANSS | 75.2 (18.7) | 84.7 (17.7) | 80.4 (17.9) | N/A |
| BPRS | 22.8 (8) | 28.3 (5.3) | 25.8 (6.9) | N/A |
AVH = auditory verbal hallucinations; BPRS = Brief Psychiatric Rating Scale; N/A = not applicable; N-AVH = no auditory verbal hallucinations; PANSS = Positive and Negative Syndrome Scale.
↵* Verbal intelligence was measured by the information survey subscale of the Wechsler Adult Intelligence Scale-Revised. Duration of illness was estimated from records review.